Daunorubicin Hydrochloride
Daunorubicin Hydrochloride 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Core Binding Factor Acute Myeloid Leukemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
3 项
已进入 III/IV 期
23 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- Kura Oncology, Inc.
- Institute of Hematology & Blood Diseases Hospital, China
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Children's Oncology Group
- MedSIR
- QuantumLeap Healthcare Collaborative
- Sunshine Lake Pharma Co., Ltd.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
- Hikma Pharmaceuticals USA Inc.
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、澳大利亚、加拿大、新西兰、Puerto Rico、西班牙、意大利、Kazakhstan、奥地利、比利时、Czechia
正在招募患者的 Daunorubicin Hydrochloride 研究
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
I 期招募中美国NCT05735184Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
不适用招募中中国NCT06529250PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
II 期招募中美国NCT06245889Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
I 期招募中美国NCT04301076Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
III 期招募中美国澳大利亚加拿大新西兰NCT03959085A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
I 期 / II 期招募中西班牙NCT07460986I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
I 期 / II 期招募中中国NCT05133882CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
II 期招募中美国NCT04493164Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
不适用招募中美国NCT04199026A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
不适用招募中中国NCT05899621Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
II 期招募中中国NCT04138719Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
III 期招募中意大利NCT04168502Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
I 期 / II 期招募中中国NCT04432714Preventive Use of PIPAC in Locally Advanced Gastric Cancer.
不适用招募中KazakhstanNCT06784765FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
I 期招募中美国NCT04659616Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
II 期招募中中国NCT06316960Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
II 期招募中中国NCT06221683Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
I 期 / II 期招募中美国NCT04047641Venetoclax Basket Trial for High Risk Hematologic Malignancies
I 期招募中美国NCT05292664Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
II 期招募中美国NCT06745076A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
II 期招募中中国NCT06928376Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
III 期招募中美国Argentina澳大利亚奥地利NCT07211958
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。